Multiple Myeloma

Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene autoleucel (cilta-cel) Out-of-Specification (OOS) in patients with Multiple Myeloma

Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

Reaching Rural Cancer Survivors Who Smoke Using Test-Based Cessation Interventions

A Phase III , Randomized, Open-Label, Multicenter Study Evaluating The Efficacy and Safety of Cevostamab in Combination with Pomalidomide and Dexamethasone vs SOC in Patients with Multiple Myeloma Who Have Received One to Three Prior Lines of Therapy

Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma

Molecular Analysis for Combination Therapy Choice (ComboMATCH)

REACH Study: Real-world Evidence to Advance Multi-Cancer Early Detection Health Equity (REACH/Galleri-Medicare study)

Expanded Access Protocol (EAP) for Subjects Receiving Lisocabtagene Maraleucel that is Nonconforming for Commercial Release

Expanded access to commercially out-of-specification brexucabtagene autoleucel for the treatment of adult patients diagnosed with an FDA approved labeled indication

A Phase 3, Multicenter, Open-Label, Randomized Trial to Compare the Efficacy and Safety of Elritercept versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in ESA-naïve Adult Participants Who Require Red Blood Cell Transfusions

Prospective Evaluation of Xerava (Eravacycline) Prophylaxis in Hematological Malignancy Patients with Prolonged Neutropenia

A Phase I Trial of Calaspargase Pegol-mknl in Combination with High Dose Cytarabine and Idarubicin in Adult Patients with Newly Diagnosed Acute Myeloid Leukemia